"Proteomic-based tests remain for many clinicians a somewhat exotic option. On other hand, doctors are often more familiar and comfortable with genetic tests, and so Biodesix's GeneStrat, which uses BioRad's droplet digital PCR to identify clinically actionable mutations in EGFR, KRAS, ALK, and BRAF in free tumor nucleic acid, has to an extent helped the company get its foot in the door with oncologists." Read the full story.